Personalized Metacognitive Training for Psychosis: A Randomized Controlled Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity Hospital, Strasbourg, France

About this trial

This study aims to compare the efficacy of classical Metacognitive Training (MCT) and personalized Metacognitive Training (P-MCT) for individuals with psychosis. MCT is a psychoeducational program derived from cognitive-behavioral therapy (CBT) that targets cognitive biases associated with psychotic symptoms. The goal is to assess which intervention is more effective to improve the overall functioning of individuals with psychosis. The study will use machine learning to personalize the treatment approach and evaluate its impact on clinical symptoms, cognitive functions, and quality of life.

Eligibility criteria

Qualifiers

Adults, 18 - 65 years of age.

Patient affiliated to health insurance

Inpatients and outpatients with DSM-5 diagnosis of schizophrenia spectrum disorder.

Presence of positive symptoms at inclusion (PANSS delusions, suspiciousness or grandiosity ≥3).

Disqualifiers

Having received MCT in the previous year.

Neurological disorder, or severe medical condition other than psychosis

A score above 5 in the "Hostility" and the "Suspiciousness" items of the PANSS Positive subscale (to preserve group dynamics).

Patient considered by his psychiatrist to be at serious risk of harm to self or others (e.g. previous aggressive or suicidal behaviors)

Trial design

Treatments tested in this trial

  • Metacognitive Training (MCT) for psychosis

Treatment groups

51 Participants
are divided into 2 treatment groups